S&P Futures
5,973.75 +15.50 (+0.26%) Dow Futures
43,965.00 +64.00 (+0.15%) Nasdaq Futures
20,982.50 +88.50 (+0.42%) Russell 2000 Futures
2,415.40 +9.60 (+0.40%) Crude Oil
71.44 -0.25 (-0.35%) Gold
2,686.20 +9.90 (+0.37%)
BriaCell Therapeutics Corp. (BCTX)
Pre-Market:
- GlobeNewswire
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations include planned Phase 3 study design expanding use of Bria-IMT™ + CPI to any cancer patient with central nervous system (CNS) metastases PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company
- MT Newswires
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study
- GlobeNewswire
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patientsMultiple outperforming patients with overall survival of over 2 yearsSurvival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors (CPIs) and/or antibody-drug conjugates (ADCs) Final median overall survival calculation for the Phase 2 study is pending, as many patients
